MIF and melanoma: In addition, MIF and CD74 have been identified as potential targets of anti-cancer therapeutics, including for cervical cancer [21], ovarian carcinoma [15], glioblastoma [22], multiple myeloma [23,24,25,26], and melanoma [12,27,28,29].